Altogether, these results indicate that the expression of the inhibitory molecule ILT2 is decreased on leukemic cells of CLL patients, but it is increased on NK cells of CLL patients, particularly in those with bad prognostic features. The gene discussed is LILRB1; the disease is B-cell chronic lymphocytic leukemia.